More on Ligand Q1 results


Ligand Pharmaceuticals (LGND -1.4%) revenues: $16M (+36.8%); royalties: $7.9M (+36.2%); materials: $5.7M (+280%); collaborative R&D: $2.4M (-44.2%); gross margin: $13.5M (+22.3%); operating income: $2.1M (+61.5%); EPS: $0.10 (+66.7%); quick assets (ex-A/R): $25.3M (+58.1%).

Q2 guidance: revenues: $9M - 9.5M; non-GAAP EPS: $0.11 - 0.13.

Full year guidance: revenues: $62M - 64M; non-GAAP EPS: $1.40 - 1.45.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs